CAMBRIDGE, Mass. — Vyome Holdings reported second-quarter 2026 results, highlighting progress with its lead VT-1953 program, expansion of its immuno-inflammatory pipeline and a stronger cash position.
The clinical-stage biopharmaceutical company said VT-1953 remains its top development priority. The topical gel is being developed for malignant fungating wounds, a serious complication that can cause malodor, pain and other symptoms.
During the quarter, Vyome received written feedback from the U.S. Food and Drug Administration on a pre-IND briefing package submitted in March that outlined its proposed pivotal clinical study strategy for VT-1953. The company said it is incorporating the FDA’s comments and plans to continue discussions with the agency through a Type C meeting.
“Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation,” said Krishna Gupta, Chairman of Vyome Holdings. “During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio.”
Vyome previously presented Phase 2 clinical data for VT-1953 at the American Association for Cancer Research meeting. The study showed statistically significant reductions in malodor, improvements in the patient-reported impact of malodor on daily life and reductions in lesion pain. No treatment-emergent adverse events were reported.
“VT-1953 remains our lead priority,” said Venkat Nelabhotla, President and Chief Executive Officer of Vyome. “The Phase 2 data presented this year demonstrated statistically significant improvements in malodor, the patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent adverse events reported.”
Vyome also expanded its pipeline through an agreement with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets being developed for potential use in autoimmune and inflammatory diseases.
Nelabhotla said the company plans to advance those programs selectively while keeping VT-1953 as its primary focus.
Vyome also received a Chinese patent covering formulation and therapeutic use claims related to its VB-1953 topical gel program for inflammatory acne.
The company ended June with approximately $7.9 million in cash and cash equivalents, up from about $5 million at the end of 2025. Total current assets were approximately $8.2 million, while stockholders’ equity was about $7.3 million.
Operating expenses for the quarter totaled approximately $874,000, including about $507,000 in research and development expenses and $365,000 in selling, general and administrative expenses.
Vyome reported a net loss attributable to common shareholders of approximately $720,000, or 10 cents per basic and diluted share.
The company said it continues to maintain a debt-free capital structure with no preferred stock or what it described as toxic financing instruments.
